SPG-302 has been developed to target the synapse in nerve cells. The synapse is the site of contact between two nerve cells or the nerve cell and muscle and enables communication via chemical signals. This communication is key for brain control of muscles for movement. One major aspect of MND is the loss of these synapses. SPG-302 has been designed to increase the number of synapses in nerve cells.
The first part of this trial took place in 2023, where the drug was tested on healthy volunteers. The second part of the Phase 1 trial moved to testing in people with motor neurone disease. This focus of this part of the trial will be testing to see whether the drug behaves in the same way in patients as it does in healthy volunteers and will also measure any changes in patients that may occur. At the completion of the four week trial participants will move to an open-label extension (OLE) component, which will allow them to keep receiving the drug for up to a year.
Recruitment for this Phase 1b trial is now complete.
For more information visit clinicaltrials.gov
